• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Revenue Growth Might Change The Case For Investing In Hims & Hers Health Stock (HIMS)

    Simply Wall St·09/25/2026 05:24:09
    Listen to the news
    • Hims & Hers Health reported 38% revenue growth after acquiring Eucalyptus and raised full year guidance, while management flagged weaker margins and pressure on cash flow in the near term.
    • The combination of faster top line expansion with falling profitability and cash generation suggests the business model is being stress tested by higher operating and integration costs.
    • We will look at how Hims & Hers Health's investment narrative is affected by strong revenue growth alongside declining margins and cash flow.

    Compare Hims & Hers Health's growth and margin trade off with a curated group of companies showing resilient fundamentals in the list of solid balance sheet and fundamentals (24 results).

    Hims & Hers Health Investment Narrative Recap

    To own Hims & Hers Health, you need to be comfortable with a story where fast revenue expansion and product breadth come first and cleaner profitability comes later. The big near term catalyst remains whether the enlarged platform can keep subscribers engaged across key categories like weight loss, sexual health, dermatology and mental health without needing sharply higher marketing spend.

    The biggest current risk sits in the margin and cash flow squeeze from integration costs, tech investment and international expansion. Recent guidance and the Eucalyptus deal suggest that pressure is not a one quarter issue. The latest share price drop reflects how sensitive the stock is to any sign that spending discipline might slip.

    The most relevant piece of recent news for this dynamic is the 38% revenue growth and raised full year outlook following the Eucalyptus acquisition. That update confirms that Hims & Hers Health can still add meaningful scale, which matters if the aim is to spread clinical, technology and marketing costs over a larger user base.

    At the same time, management has been clear that margins and cash generation are moving the other way for now. For you, the question is whether the enlarged platform, new categories and ongoing tech buildout can eventually offset those weaker economics. Execution on integration efficiency and customer retention is what turns that trade off into either an opportunity or a problem.

    Hims & Hers Health's current consensus narrative points to revenues of US$4.6b and earnings of US$241.0 million by 2029. This outlook is built on analysts assuming 21.6% yearly revenue growth and an earnings swing of about US$383.0 million, from a loss of US$142.0 million today to that projected profit level.

    Uncover why Hims & Hers Health's fair value indicates a 7% potential upside to its current price, which could narrow quickly.

    NYSE:HIMS 1-Year Stock Price Chart
    NYSE:HIMS 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts frame the real catalyst around vertical integration at Hims & Hers Health. Before this update, they were pencilling in about 31.7% annual revenue growth and roughly US$378.1 million of earnings by 2029. You can treat that as a far more aggressive story that may shift after this news.

    Explore 17 other Hims & Hers Health fair value estimates, including one that suggests as much as 485% upside from the current price.

    Decide For Yourself

    Do not just follow the ticker; dig into the data and build a conviction that is truly your own.

    Looking For More Investment Ideas Beyond Hims & Hers Health?

    If this update on Hims & Hers Health has sharpened your thinking about growth, margins and risk, use that same lens to broaden your watchlist with other companies that better match your preferred balance of quality, value and resilience.

    • If you want potential mispricing with support from solid fundamentals, scan through 30 high quality undervalued stocks that combine quality metrics with more modest expectations baked into their prices.
    • If steady income matters to your plan, review 7 dividend fortresses that pair higher yields with businesses focused on maintaining their payouts.
    • If capital protection and balance sheet strength rank highest for you, filter for 30 resilient stocks with low risk scores that score well on debt, cash and earnings stability.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.